DE69739142D1 - Pharmazeutische zusammenstellungen zur prävention und behandlung von zns-erkrankungen - Google Patents
Pharmazeutische zusammenstellungen zur prävention und behandlung von zns-erkrankungenInfo
- Publication number
- DE69739142D1 DE69739142D1 DE69739142T DE69739142T DE69739142D1 DE 69739142 D1 DE69739142 D1 DE 69739142D1 DE 69739142 T DE69739142 T DE 69739142T DE 69739142 T DE69739142 T DE 69739142T DE 69739142 D1 DE69739142 D1 DE 69739142D1
- Authority
- DE
- Germany
- Prior art keywords
- prevention
- treatment
- pharmaceutical compositions
- aryl substituted
- cns diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63176196A | 1996-04-23 | 1996-04-23 | |
PCT/US1997/006398 WO1997040011A1 (en) | 1996-04-23 | 1997-04-16 | Pharmaceutical compositions for prevention and treatment of central nervous system disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
DE69739142D1 true DE69739142D1 (de) | 2009-01-15 |
Family
ID=24532629
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69739142T Expired - Lifetime DE69739142D1 (de) | 1996-04-23 | 1997-04-16 | Pharmazeutische zusammenstellungen zur prävention und behandlung von zns-erkrankungen |
Country Status (12)
Country | Link |
---|---|
US (2) | US6603011B1 (de) |
EP (2) | EP0900200B9 (de) |
JP (2) | JP4357001B2 (de) |
AT (1) | ATE416164T1 (de) |
AU (1) | AU727976B2 (de) |
BR (1) | BR9708815B1 (de) |
CA (1) | CA2252515C (de) |
DE (1) | DE69739142D1 (de) |
DK (1) | DK0900200T5 (de) |
ES (1) | ES2318856T4 (de) |
PT (1) | PT900200E (de) |
WO (1) | WO1997040011A1 (de) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6979695B2 (en) * | 1996-04-23 | 2005-12-27 | Targacept, Inc. | Compounds capable of activating cholinergic receptors |
US20020052497A1 (en) | 2000-03-09 | 2002-05-02 | Targacept, Inc. | Compounds capable of activating cholinergic receptors |
US6166048A (en) * | 1999-04-20 | 2000-12-26 | Targacept, Inc. | Pharmaceutical compositions for inhibition of cytokine production and secretion |
AU2880699A (en) | 1998-04-02 | 1999-10-25 | R.J. Reynolds Tobacco Company | Pharmaceutical compositions and methods for use |
JP4240815B2 (ja) * | 1998-06-16 | 2009-03-18 | ターガセプト,インコーポレイテッド | アリール置換オレフィンアミンと、コリン受容体アゴニストとしてのアリール置換オレフィンアミンの使用 |
US7790757B2 (en) * | 1998-06-16 | 2010-09-07 | Targacept, Inc. | Compounds capable of activating cholinergic receptors |
US20050131034A1 (en) * | 1998-06-16 | 2005-06-16 | Caldwell William S. | Compounds capable of activating cholinergic receptors |
US6232316B1 (en) | 1998-06-16 | 2001-05-15 | Targacept, Inc. | Methods for treatment of CNS disorders |
US6455734B1 (en) | 2000-08-09 | 2002-09-24 | Magnesium Diagnostics, Inc. | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states |
AU2005201609B2 (en) * | 1999-04-20 | 2007-10-18 | Targacept, Inc | Pharmaceutical compositions for inhibition of cytokine production and secretion |
US20010031771A1 (en) | 1999-05-24 | 2001-10-18 | Gary Maurice Dull | Pharmaceutical compositions and methods for use |
JP2003501416A (ja) * | 1999-06-07 | 2003-01-14 | ターガセプト,インコーポレイテッド | 医薬組成物およびその使用法 |
WO2001008685A1 (en) * | 1999-07-30 | 2001-02-08 | Vertex Pharmaceuticals Incorporated | Acyclic and cyclic amine derivatives |
WO2001082978A2 (en) * | 2000-05-01 | 2001-11-08 | Targacept, Inc. | Imaging of nicotinic acetylcholine receptor subtypes |
EP1494994A2 (de) * | 2002-04-16 | 2005-01-12 | Rhodia Chimie | Aminierte verbindungen, die wenigstens ein allyl und ein difluormethyl tragen, und bei deren synthese angewendete verfahren |
FR2847578A1 (fr) * | 2002-11-21 | 2004-05-28 | Rhodia Chimie Sa | Composes amines porteurs d'au moins un allyle et d'un difluoromethyle et procede utile a leur synthese |
FR2838436A1 (fr) * | 2002-04-16 | 2003-10-17 | Rhodia Chimie Sa | Composes amines porteurs d'au moins un allyle et d'un difluoromethyle et procede utile a leur synthese |
AU2004318159B8 (en) * | 2004-04-02 | 2011-05-26 | Sahajanand Medical Technologies Private Limited | Polymer-based stent assembly |
US7459469B2 (en) | 2004-11-10 | 2008-12-02 | Targacept, Inc. | Hydroxybenzoate salts of metanicotine compounds |
UA88792C2 (ru) * | 2004-11-10 | 2009-11-25 | Таргасепт, Інк. | Гидроксибензоатные соли метаникотиновых соединений |
TWI389889B (zh) | 2006-05-09 | 2013-03-21 | Targacept Inc | (2s)-(4e)-n-甲基-5-〔3-(5-異丙氧基吡啶)基〕-4-戊烯-2-胺之新穎多晶型 |
US8017785B2 (en) | 2006-05-09 | 2011-09-13 | Astrazeneca Ab | Salt forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)y1]-4-penten 2-amine |
AR062860A1 (es) * | 2006-09-15 | 2008-12-10 | Astrazeneca Ab | Combinaciones terapeuticas 482 |
EP2112923A1 (de) * | 2007-01-22 | 2009-11-04 | Targacept Inc. | Intranasale, orale und sublinguale verabreichung von metanikotin-analogen |
WO2009140201A1 (en) * | 2008-05-12 | 2009-11-19 | Targacept, Inc. | Methods for preventing the development of retinopathy by the oral administration of nnr ligands |
WO2010080757A2 (en) | 2009-01-07 | 2010-07-15 | Astrazeneca Ab | Combinations with an alpha-4beta-2 nicotinic agonist |
KR20130081221A (ko) | 2010-05-20 | 2013-07-16 | 아스트라제네카 아베 | 아릴 치환된 올레핀계 아민의 신규 제조 방법 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4965074A (en) | 1985-03-05 | 1990-10-23 | Ciba-Geigy Corporation | Method of treating memory impairment |
US4684654A (en) * | 1985-08-14 | 1987-08-04 | American Cyanamid Company | 3-heteroalkyl-2,4-quinzaolinediones |
US4788206A (en) * | 1987-07-10 | 1988-11-29 | Hoffmann-La Roche Inc. | Pentadieneamides |
US4927838A (en) * | 1987-07-10 | 1990-05-22 | Hoffman-La Roche Inc. | Pyridine compounds which are useful in treating a disease state characterized by an excess of platelet activating factors |
US4786646A (en) * | 1987-07-10 | 1988-11-22 | Hoffmann-La Roche Inc. | Cyclopropylpropenamides |
US4922901A (en) | 1988-09-08 | 1990-05-08 | R. J. Reynolds Tobacco Company | Drug delivery articles utilizing electrical energy |
US5210076A (en) | 1988-09-13 | 1993-05-11 | Berliner David L | Methods of treating Parkinson's disease using melanin |
US5356906A (en) | 1989-10-27 | 1994-10-18 | The Du Pont Merck Pharmaceutical Company | (N-phthalimidoalkyl) piperidines useful as treatments for psychosis |
DE4102289A1 (de) | 1991-01-26 | 1992-07-30 | Bayer Ag | Verfahren zur herstellung von (hetero)arylalk(en/in)-ylaminen und neue (hetero)arylkinylamine |
JP3153551B2 (ja) | 1991-05-29 | 2001-04-09 | アボツト・ラボラトリーズ | 認識機能を高めるイソオキサゾールおよびイソチアゾール化合物 |
US5212188A (en) | 1992-03-02 | 1993-05-18 | R. J. Reynolds Tabacco Company | Method for treatment of neurodegenerative diseases |
US5242935A (en) | 1992-03-06 | 1993-09-07 | R. J. Reynolds Tobacco Company | Method for treatment of neurodegenerative diseases |
US5227391A (en) | 1992-04-10 | 1993-07-13 | R. J. Reynolds Tobacco Company | Method for treatment of neurodegenerative diseases |
US5723477A (en) | 1994-11-10 | 1998-03-03 | Sibia Neurosciences, Inc. | Modulators of acetylcholine receptors |
DE69535131T2 (de) * | 1995-01-06 | 2007-03-01 | Targacept, Inc. | Pharmazeutische zusammensetzungen zur vorbeugung und behandlung von störungen des zentralnervensystems |
US5616707A (en) * | 1995-01-06 | 1997-04-01 | Crooks; Peter A. | Compounds which are useful for prevention and treatment of central nervous system disorders |
US5597919A (en) | 1995-01-06 | 1997-01-28 | Dull; Gary M. | Pyrimidinyl or Pyridinyl alkenyl amine compounds |
US5616716A (en) * | 1996-01-06 | 1997-04-01 | Dull; Gary M. | (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds |
-
1997
- 1997-04-16 EP EP97921232A patent/EP0900200B9/de not_active Expired - Lifetime
- 1997-04-16 JP JP53818097A patent/JP4357001B2/ja not_active Expired - Fee Related
- 1997-04-16 AU AU27332/97A patent/AU727976B2/en not_active Ceased
- 1997-04-16 WO PCT/US1997/006398 patent/WO1997040011A1/en active IP Right Grant
- 1997-04-16 EP EP08014695A patent/EP1997806A1/de not_active Withdrawn
- 1997-04-16 PT PT97921232T patent/PT900200E/pt unknown
- 1997-04-16 DK DK97921232T patent/DK0900200T5/da active
- 1997-04-16 DE DE69739142T patent/DE69739142D1/de not_active Expired - Lifetime
- 1997-04-16 ES ES97921232T patent/ES2318856T4/es not_active Expired - Lifetime
- 1997-04-16 AT AT97921232T patent/ATE416164T1/de active
- 1997-04-16 CA CA002252515A patent/CA2252515C/en not_active Expired - Fee Related
- 1997-04-16 BR BRPI9708815-3A patent/BR9708815B1/pt not_active IP Right Cessation
-
2000
- 2000-08-21 US US09/642,351 patent/US6603011B1/en not_active Expired - Fee Related
-
2001
- 2001-10-09 US US09/973,419 patent/US6555684B2/en not_active Expired - Fee Related
-
2008
- 2008-03-11 JP JP2008060649A patent/JP2008247903A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
ES2318856T4 (es) | 2010-03-03 |
ATE416164T1 (de) | 2008-12-15 |
US6555684B2 (en) | 2003-04-29 |
EP1997806A1 (de) | 2008-12-03 |
EP0900200B9 (de) | 2009-10-21 |
AU727976B2 (en) | 2001-01-04 |
JP4357001B2 (ja) | 2009-11-04 |
WO1997040011A1 (en) | 1997-10-30 |
PT900200E (pt) | 2009-02-26 |
US6603011B1 (en) | 2003-08-05 |
CA2252515A1 (en) | 1997-10-30 |
EP0900200B1 (de) | 2008-12-03 |
CA2252515C (en) | 2006-11-07 |
JP2000509041A (ja) | 2000-07-18 |
DK0900200T3 (da) | 2009-03-30 |
BR9708815A (pt) | 2000-01-04 |
ES2318856T3 (es) | 2009-05-01 |
BR9708815B1 (pt) | 2009-01-13 |
JP2008247903A (ja) | 2008-10-16 |
US20020032206A1 (en) | 2002-03-14 |
EP0900200A1 (de) | 1999-03-10 |
AU2733297A (en) | 1997-11-12 |
DK0900200T5 (da) | 2010-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69739142D1 (de) | Pharmazeutische zusammenstellungen zur prävention und behandlung von zns-erkrankungen | |
ATE334668T1 (de) | Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen | |
ATE142877T1 (de) | Melatoninderivate zur behandlung von schlafstörungen und zur pre-anästhesie | |
ATE71629T1 (de) | Methylenphosphonalkylphosphinate, pharmazeutische zubereitungen und verfahren zur behandlung abnormalen kalzium- und phosphat-stoffwechsels. | |
IL192287A0 (en) | Pharmaceutical compositions and methods for use | |
ATE334120T1 (de) | Pharmazeutische zusammensetzungen zur vorbeugung und behandlung von störungen des zentralnervensystems | |
ATE66149T1 (de) | Pharmazeutische dosierungseinheit zur vorbeugung bzw. behandlung von klimakterischen beschwerden. | |
NO864443D0 (no) | Fremgangsmaate for fremstilling av terapeutisk aktive n-substituerte 3-piperidin- eller 3-pyridin-karboksylsyrederivater. | |
DE69300321T2 (de) | Behandlung neurodegenerativer Erkrankungen. | |
ATE217191T1 (de) | Verwendung von phanquinon zur behandlung von alzheimer's krankheit | |
ATE239470T1 (de) | Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen | |
ATE151774T1 (de) | Cyclopentanperhydrophenanthren-17-beta-(3-furyl - 3-derivate und pharmazeutische präparate davon, zur behandlung von kardiovaskulär-erkrankungen | |
DE69926794D1 (de) | Ponazuril zur behandlung von durch coccidia neurologischen und "abortigenic" verursachten erkrankungen | |
DE60121978D1 (de) | 7-CHLOR-4-HYDROXY-2-(2-PYRIDYLETHYL)-1,2,5,10-TETRAHYDROPYRIDAZINOi4,5-BöCHINOLIN-1,10-DIONE UND IHRE VERWENDUNG ZUR BEHANDLUNG VON SCHMERZEN | |
ATE242766T1 (de) | Neue derivate von benzoylalkyl-1,2,3,6- tetrahydropyridinen | |
DE69928814D1 (de) | Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten | |
ATE314339T1 (de) | Polyhydroxyphenolderivate und mittel zur vorbeugung und therapie von knochen- und knorpelkrankheiten die diese enthalten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |